MORRIS PLAINS, N.J., Oct. 19, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that it has been awarded 3 Small Business Innovation Research (SBIR) grants by the National Institutes of Health (NIH), totaling $2.1 million payable over a period of 2 years. One of the awards can be extended to 3 years with a potential $2.5 million additional funding, if certain goals and milestones are met.
